AbbVie annual debt-to-ebitda ratio
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Debt-to-EBITDA Ratio Growth & History (ABBV)
AbbVie's debt-to-ebitda ratio was 2.84 for fiscal 2025.
View full AbbVie company overviewAbbVie annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.84 | −1.04 | −26.89% |
| 2024 | 2024-12-31 | 3.88 | 1.07 | +38.14% |
| 2023 | 2023-12-31 | 2.81 | 0.40 | +16.37% |
| 2022 | 2022-12-31 | 2.41 | −0.52 | −17.67% |
| 2021 | 2021-12-31 | 2.93 | −1.95 | −39.90% |
| 2020 | 2020-12-31 | 4.88 | 0.41 | +9.11% |
| 2019 | 2019-12-31 | 4.47 | −0.02 | −0.46% |
| 2018 | 2018-12-31 | 4.49 | 1.15 | +34.26% |
| 2017 | 2017-12-31 | 3.35 | −0.12 | −3.37% |
| 2016 | 2016-12-31 | 3.46 | −0.27 | −7.25% |
| 2015 | 2015-12-31 | 3.73 | 0.27 | +7.69% |
| 2014 | 2014-12-31 | 3.47 | 1.29 | +58.97% |
| 2013 | 2013-12-31 | 2.18 | 0.08 | +3.71% |
| 2012 | 2012-12-31 | 2.10 | — | — |
AbbVie quarterly debt-to-ebitda ratio
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.53 | −1.02 | −28.71% |
| Q1 2026 | 2026-03-31 | 2.76 | −0.83 | −23.05% |
| Q4 2025 | 2025-12-31 | 2.84 | −1.04 | −26.89% |
| Q3 2025 | 2025-09-30 | 3.84 | 1.20 | +45.33% |
| Q2 2025 | 2025-06-30 | 3.55 | 0.74 | +26.52% |
| Q1 2025 | 2025-03-31 | 3.59 | 0.61 | +20.55% |
| Q4 2024 | 2024-12-31 | 3.88 | 1.07 | +38.14% |
| Q3 2024 | 2024-09-30 | 2.64 | 0.31 | +13.48% |
| Q2 2024 | 2024-06-30 | 2.80 | 0.67 | +31.64% |
| Q1 2024 | 2024-03-31 | 2.98 | 0.58 | +24.07% |
| Q4 2023 | 2023-12-31 | 2.81 | 0.40 | +16.37% |
| Q3 2023 | 2023-09-30 | 2.33 | −0.00 | −0.20% |
| Q2 2023 | 2023-06-30 | 2.13 | −0.26 | −10.84% |
| Q1 2023 | 2023-03-31 | 2.40 | 0.04 | +1.59% |
| Q4 2022 | 2022-12-31 | 2.41 | −0.52 | −17.67% |
| Q3 2022 | 2022-09-30 | 2.33 | −0.60 | −20.57% |
| Q2 2022 | 2022-06-30 | 2.39 | −0.66 | −21.75% |
| Q1 2022 | 2022-03-31 | 2.36 | −1.35 | −36.36% |
| Q4 2021 | 2021-12-31 | 2.93 | −1.95 | −39.90% |
| Q3 2021 | 2021-09-30 | 2.94 | −2.07 | −41.32% |
| Q2 2021 | 2021-06-30 | 3.05 | −2.79 | −47.80% |
| Q1 2021 | 2021-03-31 | 3.71 | −0.33 | −8.23% |
| Q4 2020 | 2020-12-31 | 4.88 | 0.41 | +9.11% |
| Q3 2020 | 2020-09-30 | 5.00 | 1.08 | +27.47% |
| Q2 2020 | 2020-06-30 | 5.85 | 2.26 | +62.94% |
| Q1 2020 | 2020-03-31 | 4.04 | −0.28 | −6.56% |
| Q4 2019 | 2019-12-31 | 4.47 | −0.02 | −0.46% |
| Q3 2019 | 2019-09-30 | 3.92 | 0.71 | +22.23% |
| Q2 2019 | 2019-06-30 | 3.59 | 0.69 | +23.95% |
| Q1 2019 | 2019-03-31 | 4.33 | 1.64 | +60.73% |
| Q4 2018 | 2018-12-31 | 4.49 | 1.15 | +34.26% |
| Q3 2018 · Sep 30 | 2018-09-30 | 3.21 | 0.20 | +6.53% |
| Q2 2018 | 2018-06-30 | 2.89 | −0.18 | −5.85% |
| Q1 2018 | 2018-03-31 | 2.69 | −0.74 | −21.50% |
| Q4 2017 | 2017-12-31 | 3.35 | −0.12 | −3.37% |
| Q3 2017 | 2017-09-30 | 3.01 | −0.62 | −17.05% |
| Q2 2017 | 2017-06-30 | 3.07 | −0.82 | −21.08% |
| Q1 2017 | 2017-03-31 | 3.43 | 0.14 | +4.14% |
| Q4 2016 | 2016-12-31 | 3.46 | −0.27 | −7.25% |
| Q3 2016 | 2016-09-30 | 3.63 | −1.93 | −34.65% |
| Q2 2016 | 2016-06-30 | 3.90 | −1.73 | −30.79% |
| Q1 2016 | 2016-03-31 | 3.29 | 0.79 | +31.50% |
| Q4 2015 | 2015-12-31 | 3.73 | 0.27 | +7.69% |
| Q3 2015 | 2015-09-30 | 5.56 | 3.16 | +131.65% |
| Q2 2015 | 2015-06-30 | 5.63 | 3.40 | +152.65% |
| Q1 2015 | 2015-03-31 | 2.50 | 0.32 | +14.54% |
| Q4 2014 | 2014-12-31 | 3.47 | 1.29 | +58.97% |
| Q3 2014 | 2014-09-30 | 2.40 | 0.27 | +12.91% |
| Q2 2014 | 2014-06-30 | 2.23 | 0.17 | +8.47% |
| Q1 2014 | 2014-03-31 | 2.19 | 0.16 | +7.71% |
| Q4 2013 | 2013-12-31 | 2.18 | 0.08 | +3.71% |
| Q3 2013 | 2013-09-30 | 2.13 | — | — |
| Q2 2013 | 2013-06-30 | 2.05 | — | — |
| Q1 2013 | 2013-03-31 | 2.03 | — | — |
| Q4 2012 | 2012-12-31 | 2.10 | — | — |
AbbVie debt-to-ebitda ratio trends
Over the last five fiscal years, AbbVie's debt-to-ebitda ratio decreased from 4.88 to 2.84, a change of −2.04. The latest reported quarter, Q2 2026, shows 2.53.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
FDA clears at-home Skyrizi induction for Crohn’s disease
AbbVie ($ABBV) received FDA approval for subcutaneous induction dosing of Skyrizi in adults with moderately to severely active Crohn’s disease. Patients can now begin treatment at home using an on-body injector, extending that delivery opti ...
AbbVie meets pivotal hidradenitis endpoint with lutikizumab
AbbVie ($ABBV) reported that lutikizumab met the main endpoint and all eight ranked secondary endpoints in the Phase 3 INTREPID trial for moderate to severe hidradenitis suppurativa. At week 16, 31.4% of treated patients achieved HiSCR75, c ...
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
